10:24 AM EDT, 08/01/2025 (MT Newswires) -- Orchestra BioMed ( OBIO ) priced an underwritten public offering of 9.41 million shares at $2.75 apiece and 5.1 million prefunded warrants at $2.7499 each for proceeds of $40 million.

Underwriters have a 30-day option to buy up to 2.18 million additional shares, the company said Friday in a statement.

Proceeds will be for funding the atrioventricular interval modulation therapy program, clinical trials and general corporate purposes, the company said.

The offering is expected to close on Monday

Orchestra BioMed ( OBIO ) shares fell 13% in recent trading Friday.

Price: 2.66, Change: -0.40, Percent Change: -13.07